Home » Stocks » AZN

AstraZeneca plc (AZN)

Stock Price: $52.61 USD 0.01 (0.02%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $52.70 +0.09 (0.17%) Nov 27, 4:59 PM

Stock Price Chart

Key Info

Market Cap 138.08B
Revenue (ttm) 25.87B
Net Income (ttm) 2.42B
Shares Out 2.62B
EPS (ttm) 0.95
PE Ratio 55.38
Forward PE 22.83
Dividend $1.40
Dividend Yield 2.66%

Stock Quote

Trading Day November 27
Last Price $52.61
Previous Close $52.60
Change ($) 0.01
Change (%) 0.02%
Day's Open 51.58
Day's Range 51.44 - 52.77
Day's Volume 14,783,164
52-Week Range 36.15 - 64.94

More Stats

Market Cap 138.08B
Enterprise Value 151.97B
Earnings Date (est) Feb 11, 2021
Ex-Dividend Date Aug 13, 2020
Shares Outstanding 2.62B
Float 2.62B
EPS (basic) 0.95
EPS (diluted) 0.95
FCF / Share 1.35
Dividend $1.40
Dividend Yield 2.66%
Earnings Yield 1.81%
FCF Yield 2.56%
Payout Ratio 147.40%
Shares Short 6.29M
Short Ratio 1.38
Short % of Float 0.24%
Beta 0.30
PE Ratio 55.38
Forward PE 22.83
P/FCF Ratio 39.11
PS Ratio 5.34
PB Ratio 11.90
Revenue 25.87B
Operating Income 4.25B
Net Income 2.42B
Free Cash Flow 3.53B
Net Cash -13.89B
Net Cash / Share -5.29
Gross Margin 75.51%
Operating Margin 16.44%
Profit Margin 9.30%
FCF Margin 13.65%
ROA 5.22%
ROE 17.71%
ROIC 17.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (26)

Buy 18
Overweight 0
Hold 5
Underweight 1
Sell 2

Analyst Consensus: Buy

Price Target

$62.02*
(17.89% upside)
Low
42.1
Current: $52.61
High
77.1
Target: 62.02
*Average 12-month price target from 22 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue24,38422,09022,46523,00224,70826,54725,80627,97333,59133,269
Revenue Growth10.38%-1.67%-2.33%-6.9%-6.93%2.87%-7.75%-16.72%0.97%-
Gross Profit19,46317,15418,14718,87620,06220,70520,54522,58027,56526,880
Operating Income2,9243,3873,6774,9024,1142,1373,7128,14811,31211,494
Net Income1,2272,0502,8683,4062,8261,2352,5716,2709,9508,081
Shares Outstanding1,3011,2671,2661,2651,2641,2621,2521,2611,3611,438
Earnings Per Share0.520.851.191.381.120.491.022.473.632.79
EPS Growth-39.41%-28.27%-14.13%23.77%127.55%-51.96%-58.7%-31.86%30.16%-
Dividend Per Share1.401.401.401.402.352.802.802.852.702.41
Dividend Growth0%0%0%-40.43%-16.07%0%-1.75%5.56%12.03%-
Operating Cash Flow4,8613,8314,7305,2345,1748,7928,7199,53612,36813,854
Capital Expenditures-942-1,031-1,243-1,364-1,281-854-673-473-737-708
Free Cash Flow3,9192,8003,4873,8703,8937,9388,0469,06311,63113,146
Cash & Equivalents6,2185,6804,5545,9026,8537,15510,0138,52411,81912,550
Total Debt18,22719,11317,80716,80815,05310,84310,37610,3109,3289,222
Net Cash / Debt-12,009-13,433-13,253-10,906-8,200-3,688-363-1,7862,4913,328
Assets61,37760,65163,35462,52660,05658,59555,89953,53452,83056,127
Liabilities46,78146,60746,71245,85741,54738,94932,64629,58829,36432,717
Book Value13,12712,46814,96014,85418,49019,62723,22423,73123,24023,213
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AstraZeneca plc
Country United Kingdom
Employees 70,600
CEO Pascal Soriot

Stock Information

Ticker Symbol AZN
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: AZN
IPO Date May 12, 1993

Description

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.